[
    {
        "drug": {
            "name": "pazopanib"
        },
        "phenotypes": {
            "HLA-B": "*57:01 positive",
            "UGT1A1": "Poor Metabolizer"

        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 2)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section2"
        },
        "implications": {
            "HLA-B": "May result in higher adverse reaction risk (liver enzyme elevations). Monitor liver function tests regardless of genotype.",
            "UGT1A1": "Results in higher adverse reaction risk (hyperbilirubinemia)."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)"
    },
    {
        "drug": {
            "name": "pazopanib"
        },
        "phenotypes": {
            "HLA-B": "Any not handled in guideline",
            "UGT1A1": "Poor Metabolizer"

        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 2)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section2"
        },
        "implications": {
            "HLA-B": "n/a",
            "UGT1A1": "Results in higher adverse reaction risk (hyperbilirubinemia)."
        }
    },
    {
        "drug": {
            "name": "pazopanib"
        },
        "phenotypes": {
            "HLA-B": "*57:01 positive",
            "UGT1A1": "Any not handled in guideline"

        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 2)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section2"
        },
        "implications": {
            "HLA-B": "May result in higher adverse reaction risk (liver enzyme elevations). Monitor liver function tests regardless of genotype.",
            "UGT1A1": "n/a"
        }
    }
]